Therapeutic approaches in Parkinson's disease and related disorders

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

(2015) C. Warren Olanow et al.   ANNALS OF NEUROLOGY

Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease

(2015) Maryka Quik et al.   BIOCHEMICAL PHARMACOLOGY

Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease

(2015) Karl Kieburtz et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Can Parkinson’s disease be cured by stimulating neurogenesis?

(2015) Thomas Foltynie   JOURNAL OF CLINICAL INVESTIGATION

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease

(2015) Elvira Valera et al.   Journal of Neuroinflammation

Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial

(2015) Werner Poewe et al.   LANCET NEUROLOGY

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations

(2015) Benjamin Dehay et al.   LANCET NEUROLOGY

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

(2015)   LANCET NEUROLOGY

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy

(2015) Brian Spencer et al.   Molecular Neurodegeneration

New clinical trials for nonmotor manifestations of Parkinson's disease

(2015) Anette Schrag et al.   MOVEMENT DISORDERS

GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson’s disease

(2015) D.B. Hoban et al.   NEUROSCIENCE

Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications

(2015) Christine Kaindlstorfer et al.   NEUROTOXICITY RESEARCH

Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease

(2015) Asako Yoritaka et al.   PARKINSONISM & RELATED DISORDERS

Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism

(2015) Stanley B. Prusiner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease

(2015) Anne Schwerk et al.   Regenerative Medicine

Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial

(2015) Manabu Ikeda et al.   Alzheimers Research & Therapy

A combination Alzheimer’s therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice

(2015) Latha Devi et al.   Molecular Brain

Basal Ganglia Circuits as Targets for Neuromodulation in Parkinson Disease

(2015) Mahlon R. DeLong et al.   JAMA Neurology

Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD

(2014) Silke Nuber et al.   ACTA NEUROPATHOLOGICA

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

(2014) Markus Mandler et al.   ACTA NEUROPATHOLOGICA

Glucocerebrosidase is shaking up the synucleinopathies

(2014) Marina Siebert et al.   BRAIN

The green tea polyphenol (−)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios

(2014) Heike J. Wobst et al.   FEBS LETTERS

Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

(2014) D. Games et al.   JOURNAL OF NEUROSCIENCE

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial

(2014) Phillip A Low et al.   LANCET NEUROLOGY

ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo

(2014) Brian Spencer et al.   MOLECULAR THERAPY

Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice

(2014) J. Mark Cooper et al.   MOVEMENT DISORDERS

Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial

(2014) H. Kaufmann et al.   NEUROLOGY

The emerging role of nutrition in Parkinson's disease

(2014) Stacey E. Seidl et al.   Frontiers in Aging Neuroscience

Ketogenic Diet in Neuromuscular and Neurodegenerative Diseases

(2014) Antonio Paoli et al.   Biomed Research International

Products of the Parkinson's disease-related glyoxalase DJ-1, D-lactate and glycolate, support mitochondrial membrane potential and neuronal survival

(2014) Y. Toyoda et al.   Biology Open

Can parkin be a target for future treatment of Parkinson's disease?

(2013) Shin-ichiro Kubo et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy

(2013) Elvira Valera et al.   GLIA

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

(2013) Anthony HV Schapira et al.   LANCET NEUROLOGY

The genetics of Parkinson's disease: Progress and therapeutic implications

(2013) Andrew B. Singleton et al.   MOVEMENT DISORDERS

Mutations in COQ2 in Familial and Sporadic Multiple-System Atrophy

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies

(2013) Elvira Valera et al.   PHARMACOLOGY & THERAPEUTICS

GDNF, NGF and BDNF as therapeutic options for neurodegeneration

(2013) Shelley J. Allen et al.   PHARMACOLOGY & THERAPEUTICS

The Role of Autophagy in Parkinson's Disease

(2013) M. A. Lynch-Day et al.   Cold Spring Harbor Perspectives in Medicine

A randomized trial of mesenchymal stem cells in multiple system atrophy

(2012) Phil Hyu Lee et al.   ANNALS OF NEUROLOGY

Hsp70 Alters Tau Function and Aggregation in an Isoform Specific Manner

(2012) Kellen Voss et al.   BIOCHEMISTRY

A randomized clinical trial of lithium in multiple system atrophy

(2012) Francesco Saccà et al.   JOURNAL OF NEUROLOGY

Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson’s disease

(2012) Paula Desplats et al.   Molecular Neurodegeneration

Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type α-Synuclein and Reduces the Pathology in an α-Synuclein Model of LBD

(2012) Brian Spencer et al.   MOLECULAR THERAPY

Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study

(2012) Bruno Dubois et al.   MOVEMENT DISORDERS

The many faces of α-synuclein: from structure and toxicity to therapeutic target

(2012) Hilal A. Lashuel et al.   NATURE REVIEWS NEUROSCIENCE

Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds

(2011) Mario Caruana et al.   FEBS LETTERS

Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's Disease

(2011) R Mark Richardson et al.   MOLECULAR THERAPY

The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

(2011) E. Ilijic et al.   NEUROBIOLOGY OF DISEASE

Does vigorous exercise have a neuroprotective effect in Parkinson disease?

(2011) J. E. Ahlskog   NEUROLOGY

Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model

(2011) Nadia Stefanova et al.   NEUROTOXICITY RESEARCH

Vaccination for Parkinson's disease

(2011) A. Schneeberger et al.   PARKINSONISM & RELATED DISORDERS

In vivo demonstration that  -synuclein oligomers are toxic

(2011) B. Winner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity

(2010) Karin M. Danzer et al.   FASEB JOURNAL

Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases

(2010) Maurizio Renna et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Synergistic Interactions between A , Tau, and  -Synuclein: Acceleration of Neuropathology and Cognitive Decline

(2010) L. K. Clinton et al.   JOURNAL OF NEUROSCIENCE

Treatment of the nonmotor symptoms of Parkinson disease

(2010) Werner Poewe   Nature Reviews Neurology

Cell-to-cell transmission of non-prion protein aggregates

(2010) Seung-Jae Lee et al.   Nature Reviews Neurology

Cognitive Functions in a Patient With Parkinson-Dementia Syndrome Undergoing Deep Brain Stimulation

(2009) Hans-Joachim Freund et al.   ARCHIVES OF NEUROLOGY

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of  -synuclein

(2009) P. Desplats et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein Misfolding and Neurodegeneration

(2008) Claudio Soto et al.   ARCHIVES OF NEUROLOGY

Cathepsin D Is the Main Lysosomal Enzyme Involved in the Degradation of α-Synuclein and Generation of Its Carboxy-Terminally Truncated Species†

(2008) Daniel Sevlever et al.   BIOCHEMISTRY

Rasagiline is neuroprotective in a transgenic model of multiple system atrophy

(2007) Nadia Stefanova et al.   EXPERIMENTAL NEUROLOGY